AXL kinase inhibitorsInnovative leads with initial proof-of-concept
The LDC provides biopharmaceutical companies with unique access to high-quality pharmaceutical leads based on the most innovative research findings from leading research institutions. All leads come with proof-of-concept in animal models, solid IP protection and comprehensive data packages, enabling a seamless transition into an industry partner’s lead optimization and drug development environment. Following licensing, the LDC offers the industrial partner the option of further exchange with academic project stakeholders, in order to advance the drug development optimally with ample scientific input.
Access to prime external innovation
For projects originating from Max Planck institutes, Max Planck Innovation is your partner for structuring licensing or co-development deals. For all other projects, negotiations will be coordinated by the LDC or the technology transfer agency in charge.
